Effective Combination Therapy for Moderate to Severe Acne

Evidence indicates that fairly short courses of oral antibiotic therapy when paired with a proven topical regimen can establish long-term efficacy.

BY LAWRENCE F. EICHENFIELD, MD

Dermatologists have access to a broad armamentarium for the treatment for adolescent acne. In treating more severe cases, oral antibiotics in addition to retinoids or retinoid combinations have proven particularly useful. However, questions continue to linger regarding the appropriate duration of therapy and how effective topical therapies can be after oral antibiotics have been discontinued. Fortunately, recent studies have clarified these issues and offered encouraging evaluations for effective combination regimens. One of these studies is the ACCESS trial, the results of which were published in recent months.

ACCESS DATA

With the evolution of topical combination therapies—which include retinoids and antimicrobials—a question behind the study was to what degree these agents improve acne when used along with oral antibiotics. How much better do our more severe patients get with topical combinations plus oral antibiotics, as compared to oral antibiotics alone? In addition, the ACCESS study sought to address what happens after the discontinuation of oral antibiotics when patients continue to use a combination retinoid/antimicrobial. Do they flare off of the oral antibiotics, or can the maintenance regimen of topicals maintain their improved acne?

The ACCESS study evaluated the combination agent adapalene 0.1% and benzoyl peroxide 2.5% (Epiduo, Galderma). The study was designed for patients with severe acne and was split into two parts. The first 12-week arm assessed the efficacy of adapalene 0.1% and benzoyl peroxide 2.5% (A/BPO) in a fixed dose used in combination with doxycycline 100mg once-daily, as compared to doxycycline alone (n=459).1 In terms of total lesion counts, the combination group clearly fared better than doxycycline alone group as early as Week 2. Moreover, the A/BPO group saw statistical significant improvement in total inflammatory and non-inflammatory lesion counts by the end of 12 weeks.

This part of the study showed the benefits of topical treatment with A/BPO with doxycycline, as compared to doxycycline alone, resulting in 64 percent reduction in lesion count—21 to 24 percent higher (depending on the type of lesion) in the combination group than with doxycycline alone. Additionally, digital fluorescent photogra-phy showed a marked reduction in *P. acnes* in the A/BPO group.

While these numbers are consistent with expectations based on clinical experience and previous data, the relatively high percentage (nearly 35 percent) of patients treated with the A/BPO combination that achieved clear or almost clear status was impressive, compared to less than 10 percent for doxycycline alone.

The second part of the study evaluated what occurs after stopping oral doxycycline, with and without contin-
Clinical Focus: Pediatrics

Topical agents, this should be avoided. In general, after an adequate course of oral antibiotics used with topical retinoids or retinoid combination therapies, most all individuals should be transitioned to a topical regimen alone. This data may also prompt researchers and clinicians to ponder the possibilities of other combination approaches incorporating retinoids and antimicrobials. For example, there are several antimicrobial combinations with lower strength BPO plus clindamycin that might be useful in regimens of care with topical retinoids. The advantage of a lower strength BPO is that it potentially makes the formulation less irritating. Nevertheless, the particular combination employed in the ACCESS trial has shown a great deal of benefit itself and also benefits from the recent launch of pump delivery technologies. Unit dosing is generally much appreciated by patients, as it takes away a variability of under- or over-use of the agent, and it may improve adherence.

Conclusion

The ACCESS data confirm current guidelines advising use of topical retinoid combination regimens for moderate to severe acne. Additionally, these trials importantly reiterate that patients can likely continue to benefit from ongoing use of a topical retinoid/antimicrobial combination after the discontinuation of oral antibiotics. Moreover, the data provide good evidence that fairly short courses of oral antibiotic therapy when paired with a good topical regimen can establish long-term efficacious therapy for a majority of patients with acne.

Dr. Eichenfield has served as an investigator and past consultant for Galderma, Valient, GSK-Stiefel, and Medicis.

Lawrence F. Eichenfield, MD, is chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego, and professor of pediatrics and medicine (dermatology) at the University of California, San Diego (UCSD) School of Medicine.

These studies should add to physicians’ overall comfort level with appropriate use of oral antibiotics for fairly short durations, plus combination topical agents.